Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 5/20 | 0.50 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 3/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL219864 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL3805427 | 0.87 | LMNA (0.52) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL4430842 | 0.82 | LMNA (0.56) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL4431806 | 0.82 | LMNA (0.56) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL4430839 | 0.82 | LMNA (0.56) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL9293928 | 0.82 | LMNA (0.59) | LMNASMN1; SMN2HTTCTSKCTSS | |
| Hydrochloric Acid SCHEMBL6534947 | 0.81 | LMNA (0.55) | LMNASMN1; SMN2CA1CA2CA12 | |
| SCHEMBL4473071 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSKCTSS | |
| SCHEMBL6216286 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSKCTSS | |
| SCHEMBL5640402 | 0.81 | LMNA (0.58) | LMNASMN1; SMN2HTTCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |
| EP-1888567-B1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI AVENTIS (FR) | 2009-12-16 | — | — | EP | disclosed |
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2008-07-10 | — | — | US | disclosed |
| EP-1888567-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | Sanofi-Aventis (FR) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006122661-A1 | HETEROARYL-CARBOXYLIC ACID (SULFAMOYL ALKYL) AMIDE - DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS (DE) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167346-A1 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | TFPI, SERPINC1, PLAT | LMNA 1704/4885SMN1; SMN2 3949/4885CA1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.